Search Results
Results found for "Stuart Maudsley"
- Time is your enemy, GPCRs are your friend
Stuart Maudsley on how an aging physiological context affects #GPCR signaling #drgpcr.
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Terry's Corner : Stop Chasing Affinity and Start Reading the System In this week’s cornerstone Terry’ Lauren Slosky, Stuart Maudsley and Yamina Berchiche invite your insights for Volume II.
- 📰 GPCR Weekly News, March 4 to 10, 2024
Stuart Maudsley, Nicole Perry-Hauser, Lauren Slosky, Cesare Orlandi, and Simone Prömel. GPCR University Save the date for our upcoming workshop starting May 9th, 2024, featuring Dr.
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
But when the science starts to drift, teams often discover something uncomfortable. When they do not, it starts to fail quietly. The team is talented, but momentum starts leaking. 👉 Early-stage biotech hiring fails at this point, What Survival Traits Look Like in Real Biotech Work 👉 When founders start paying attention, they realize They start asking whether that person can still be effective when the ground shifts under their feet.
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
It means a commitment to continuous improvement — starting with the highest-friction gaps and working
- To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from...
September 2022 To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started
- How to Avoid the Most Common Gaps in Your Biotech Pitch
doesn’t immediately tell them who it’s for, why it matters, and what makes it different, then they start They have to guess why it matters, what the application is, and whether it fits. ✅ Start with relevance People start leaning in. You stop explaining. People start connecting the dots for you. 👉 This is what clarity creates. Start refining your message. Ready to Break Your Bottlenecks?
- Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game
struggling to predict structures from scratch, Alessandro and others could now use AI-generated models as starting “…now you have a plethora of 400 models that you can start with molecular dynamics, docking, virtual Start with our GPCR training program and get hands-on with virtual tools shaping the future of drug discovery
- Asking Better Questions in Science: A Practical Guide for Emerging Researchers
Asking Better Questions in Science JB’s story makes one thing clear: asking better questions in science starts It starts by noticing what grabs your attention, what sparks those quiet “aha” moments during a lecture is the practical side of asking better questions in science: not the wording, but the willingness to start collaboration with David Hodson, every major leap—from early ligand design to GPCR visualization tools—started
- The One Reason Why Biotech Startups Fail More Often Than They Should
Yet over time, alignment fades, and decisions start to feel disconnected. 👉 Many founders ask why biotech startups fail not after a collapse, but when the company starts to feel harder to run without a clear decisions The turning point for many biotech startups comes when strategy stops being a document and starts Instead of adding more work to feel safer, teams start designing fewer experiments with sharper intent trusts execution because work is clearly tied to strategic intent. ✅ The company stops reacting and starts
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
Where Biotech Misalignment Starts 👉 Most misalignment doesn’t start with conflict. It starts with silence. You assume your CSO knows where you’re headed. Your BD person starts framing it for a niche diagnostic use. The board expects an IND package. Real biotech traction starts when decisions are driven by shared strategy, not disconnected deliverables tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
Starting From Zero: Growing With a Mentor When Alessandro joined Prof. At the start it was difficult, because you see all these projects and you think, ah, I don’t know… but
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
consistency: Can you show that your process will be scalable, repeatable, and GMP-compliant from the start Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start They start by asking: What would FDA approval actually require from us, and what decisions need to reflect Instead of collecting interesting data, you start collecting strategic evidence . tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start
- Building Backwards: Why Top-Down Models Could Revolutionize Pain Research
Rather than starting with a molecular hypothesis, Serafini’s team noticed that hamsters infected with By starting with phenotype-first studies , Serafini’s approach offers a translational lens more tightly
- How Collaboration Drives GPCR Discoveries
Watch Episode #177 Some scientific breakthroughs don’t start with a grant or a perfectly architected They start with a chance email, an unexpected visitor at the door, or the moment a team realizes the Their collaboration didn’t start as a big strategic play. It started with curiosity, openness, and the humility to admit that better answers required better tools
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
“There was this very interesting phenotype the lab found where, as a mouse was starting to enter what we consider the chronic pain range, the mice that were constitutively RGS4 knocked out started recovering
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
Teams start planning around delays BD and investor messaging drifts Timelines become aspirational rather “we hope next year is better” → to “our cadence ensures it will be.” ✅ If you want a stronger 2025, start tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start
- Scientific Isolation: The Real Reason Early Biotechs Lose Traction
’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts interesting but unready.” 3️⃣ Internal Alignment Frays When “the science” drives everything, different teams start tradeoffs, or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
Some breakthroughs don’t start with a grant or a roadmap — they start with a question no one expects It was the start of a scientific partnership with the potential to shift how GPCRs could be visualized What started as one molecule request is now a platform vision — a future where any GPCR could be illuminated
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
years of hard-won insight distilled into accessible, high-impact content designed for learners just starting
- Pharmacology Isn't What You Think—It's So Much More
. 👉 Start your journey with Terry’s foundational series Unlock "Unique Role of Pharmacology" now
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
on both sides of the biotech fundraising table Why biotech fundraising breaks before diligence even starts 👉 This is where intellectual property gaps start to matter. the IP does not map cleanly to how the company plans to generate returns, the fundraising narrative starts tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
Some breakthroughs don’t start with a hypothesis. They start with a sentence that freezes the room. talk about the emotional side of discovery — the instant where the experiment stops being data and starts
- What If Your Data is Lying to You? The Calcium Assay Dilemma
If you're starting out in pharmacology, this lesson gives you the interpretive tools to ask smarter questions
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Several of the drugs shown throughout the conference are starting their clinical trials. excellent scientists felt like a dream come true, and Maria enjoyed giving advice to those who are starting
- Exclusive Access: Terry's Corner is LIVE + Your Premium Member Discount!
Explore Terry's Corner Better decisions start with better pharmacology.
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
“Companies started shutting down neuroscience and GPCR programs. But I stayed,” Sokhom said.
- From Lab Bench to Boardroom: The Unexpected Path of a Medicinal Chemist
Maria Majellaro Maria’s career didn’t start with a desire to launch a company.
- From Pipettes to Platforms: The Evolution of GPCR Research
Where once a well-run assay was the pinnacle, now it’s the foundation — a starting point for more ambitious What started as hand-built assays on ice has become integrated platforms for drug discovery, systems
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
SAR that breaks your QSAR model, and missed opportunities to design more efficient ligands from the start If you’re ready to stop guessing and start optimizing, this lecture is your next step.




























